Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$110.69 USD
+2.54 (2.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $110.69 0.00 (0.00%) 5:14 PM ET
4-Sell of 5 4
C Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.69 USD
+2.54 (2.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $110.69 0.00 (0.00%) 5:14 PM ET
4-Sell of 5 4
C Value D Growth A Momentum D VGM
Zacks News
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Why Is Pediatrix Medical Group (MD) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cencora (COR) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Company News for Apr 30, 2024
by Zacks Equity Research
Companies In The News Are: DPZ, BEN, ON, RVTY.
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Revvity (RVTY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 4.26% and 0.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?
by Zacks Equity Research
Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Three Reasons to Retain Revvity (RVTY) Stock in Your Portfolio
by Zacks Equity Research
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
Revvity's (RVTY) New Launch to Boost Research Productivity
by Zacks Equity Research
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
Revvity (RVTY) Q4 Earnings Top, EPS View Above Expectation
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results showcase the decline in segmental revenues. However, the company's earnings and revenues beat their respective estimates.
Compared to Estimates, Revvity (RVTY) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Revvity (RVTY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for its Life Sciences and Diagnostics franchises.
Revvity (RVTY) Launches New Molecular Testing for Newborns
by Zacks Equity Research
Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
Company News for Oct 31, 2023
by Zacks Equity Research
Companies in The News Are: HLIT, JKS, RVTY, ON.
Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.
Compared to Estimates, Revvity (RVTY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of -0.84% and 3.10%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?